Hartalega's FY21 full year earnings is expected to leapfrog to RM2.8bil or EPS of RM0.83/share.

Superior margin ahead of its peers

TopGlove's profit is expected to jump by 5% for every 1% hike in ASP. Hartalega's profit is expected to jump 11% for every 1% hike in ASP. This is due to extreme efficiencies at NGC plant compared to its peers. Hartalega's plant are almost 100% automated.

ASP hike of 35% - 40% for June

Net profit to jump 350% - 400% from June and onwards. Assuming a 35% hike in ASP, Harta's net profit is expected to jump by 385%. Net profit for next quarter is expected to be between RM450mil - RM600mil.

Largest base in US

Harta's base in US is 55%. Compared to its peers, its the largest.

Antimicrobial glove catalyst

Game changer for Harta. No other big 4 glove companies is able to produce antimicrobial glove at a mass scale. This gloves has already been sold in Europe. Once FDA is obtain by year end, Harta is expected to command another premium to its share price.

Director acquisition of shares

Compared to its peers, only Harta's directors/founders have been acquiring shares at high prices. This is a strong sign that the management has absolute confidence in the company.

Valuation

Harta is undervalued compared to its peers at current valuation of 15x FY21 PE. Ascribe a 30x FY21 PE to arrive at RM24.80.

We believe Harta fully deserves to be the largest market cap company in Malaysia.